Twelve Burkholderia pseudomallei isolates collected over a 32-month period from a patient with chronic melioidosis demonstrated identical multilocus sequence types (STs). However, whole-genome sequencing suggests a polyclonal infection. This study is the first to report a mixed infection with the same ST.
B
urkholderia pseudomallei is a Gram-negative bacterium that causes the potentially fatal disease melioidosis (1) . Melioidosis is the most common cause of community-acquired bacteremic pneumonia in the tropical Top End of the Northern Territory, Australia (2) , with annual infection rates in recent years of up to 50 per 100,000 people (3) . Multilocus sequence typing (MLST) is a widely adopted genotyping method for characterizing bacterial pathogens, including B. pseudomallei (4) (5) (6) . MLST has been used to demonstrate that B. pseudomallei is among the most recombinogenic bacterial species studied to date, with a recombinationto-mutation ratio more than twice that of Streptococcus pneumoniae (7) . Although useful for identifying strain relatedness, MLST is insensitive to genome-wide variation. To investigate genome-wide variation and better detect polyclonal infections, whole-genome sequencing is essential.
Case history. The Darwin Prospective Melioidosis Study (DPMS) has documented all known Top End melioidosis cases since October 1989 (2). The 103rd enrolled DPMS patient, P103, was a 49-year-old male who had a history of asthma and chronic lung disease and who had received intermittent therapy with oral prednisolone. Although P103 had positive B. pseudomallei serological titers since he was first tested in August 1990, serology itself is not an accurate diagnostic tool, particularly in regions where melioidosis is endemic; culture confirmation is required for a definitive melioidosis diagnosis (8) . Given his positive serology, P103's sputum was repeatedly tested for B. pseudomallei, but it remained culture negative (9, 10) until September 1994, when B. pseudomallei isolate MSHR338 was obtained. Upon diagnosis, standard therapy comprising 2 weeks of intravenous ceftazidime followed by 3 months of oral doxycycline was commenced. Despite an improvement in symptoms, the sputum was again culture positive in December 1994. An additional round of intravenous ceftazidime followed by oral therapy with various combinations of doxycycline, trimethoprim-sulfamethoxazole, and chloramphenicol was administered. However, P103 still remained culture positive, with isolates retrieved from sputum or throat specimens 4, 7, 15, 21, and 30 months after obtaining MSHR338 ( MLST analysis. MLST was initially performed on seven isolates derived from six clinical specimens over a 32-month period (Table 1) . DNA was extracted from single purified colonies as previously detailed (12) . All seven isolates were sequence type 243 (ST-243), which has only been identified in isolates from this patient (http://bpseudomallei.mlst.net/).
Genomic analysis. Illumina GAIIx or HiSeq 2000 (Illumina, Inc., San Diego, CA) whole-genome sequencing was performed on 12 P103 B. pseudomallei isolates, including 5 isolates derived from three clinical specimens to more thoroughly sample within-host B. pseudomallei diversity (Table 1) . Comparative genomic analyses were performed using SPANDx v2.3 (13) , and maximum parsimony phylogenetic reconstruction of orthologous core singlenucleotide polymorphism (SNP) variants was carried out using PAUP* v4.0b (14) . 454 GS FLXϩ sequencing (454 Life Sciences, Branford, CT) was also performed on MSHR338. The 454 reads were combined with Illumina data for de novo genome assembly, as previously described (11), and checked for errors with iterative correction of reference nucleotides (iCORN2) (15) using the Illumina reads. The final MSHR338 hybrid assembly (GenBank accession no. ATJY00000000.1) is in 59 high-quality contigs totaling 7,317,227 bp.
Phylogenetic reconstruction of the P103 genomes using default (i.e., permissive) SNP density filtering parameters in SPANDx (whereby only regions containing Ն3 SNPs within 10 bp are excluded [16] ) demonstrated that MSHRs 346A, 346B, 376, 391, 443, 2845, and 2849 were identical. MSHRs 487, 2844, and 2848 each differed by one SNP (Fig. 1A) . In contrast, 842 SNPs separated MSHR338 from the dominant genotype. No large deletions (Ͼ50 bp) were observed in any P103 strains compared with MSHR338, although 36 unique insertions or deletions (indels) were found in MSHR338 (Table 2) . No indels were found among the other 11 strains. Given the relatively large genetic distance between MSHR338 and the subsequent P103 isolates, the potential for additional genotypes within the original MSHR338 culture stock was explored further. This stock was plated onto chocolate agar, and 10 individual colonies were screened using allele-specific real-time PCR (17) interrogation of an SNP at position 332 of the MSHR338 Seq0033 contig, which differentiates MSHR338 from other P103 isolates. All 10 colonies matched the dominant genotype. One colony (MSHR338 -5) was fully sequenced (Table 1) and was identical to the dominant genotype, confirming the presence of this genotype in the original clinical specimen.
Given the ST-243 diversity in P103, the relative roles of recombination and mutation were investigated. A recombination filtering parameter (i.e., excluding regions with Ն3 SNPs within 300 bp) was first applied to the 12 P103 genomes. Using this filter, the majority of SNP differences (n ϭ 778; 94%) in MSHR338 were removed (Fig. 1B) . Closer examination of these SNPs in Integrative Genomics Viewer 2.3.34 (18) showed that the vast majority (99.9%) of SNPs in MSHR338 were colocated within a 1.3-Mbp region (Fig. 2) . These results strongly suggest that one or more recent recombination events led to the ST-243 diversity in P103. Given that no other isolates with similar variants were found in P103, this recombination event probably occurred prior to infection, although the possibility of within-host recombination with an unrelated ST that was not sampled or that became extinct cannot be ruled out.
To the best of our knowledge, this study is the first to report a polyclonal infection with the same ST, and it demonstrates that MLST can be insensitive for detecting polyclonality. Two previous studies of mixed B. pseudomallei infections using various genotyping methods estimated a B. pseudomallei polyclonal infection rate of between 1.5 and 28% (19, 20) ; however, the true rate remains unknown. Within-host evolution in P103 is unlikely given the relatively low diversity in other reported melioidosis cases (20) (21) (22) , including a 12-year chronic-carriage case (11) . We therefore conclude that the genotypes recovered from P103 resulted from inoculation with two or more genotypes. The MSHR338 genotype was only detected in the first culture specimen from this patient and at low frequency (Ͻ10%) and might have been missed with less intensive sampling. Increased adoption of whole-genome sequencing, in combination with greater sampling efforts, will unveil further instances of polyclonality in clinical specimens. We speculate that polyclonal infection may have led to the difficulties in pathogen eradication observed in this case. However, a greater understanding of pathogen evolution and adaptation within the human host is needed to better inform the precise clinical ramifications of polyclonal infections. Nucleotide sequence accession number. The sequence determined in this study has been deposited in GenBank under accession no. ATJY00000000.1.
